The quarter reflected steady revenue growth but underscored challenges in profit conversion, as seen in declining operating ...
DexCom reported Q4 revenue of $1.11 billion, surpassing estimates. The company reaffirmed its 2025 outlook while analysts ...
Over the past decade, the rising cost of insulin epitomized the broader systemic issue of higher healthcare out-of-pocket ...
DexCom (NASDAQ: DXCM) is a healthcare company that makes continuous glucose monitoring (CGM) devices, which help people track ...
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an ...
Living with Type 1 diabetes is a numbers game. There’s not a moment in the day free from the burden of tracking your blood ...
Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated ...
A U.K. court has ruled against Abbott in a trademark infringement case the company had brought over the design of a rival ...
An Apple Watch, which integrates easily into the Dexcom CGM ecosystem ... Until then, if you need a primer on continuous glucose monitoring, we’re happy to oblige.
Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback